Abstract
γ-Hydroxybutyric acid (GHB) is an abused substance that occurs naturally in the basal ganglia. Electrophysiological recordings of membrane voltage and current were made to characterize the effects of GHB on dopamine neurons in the ventral tegmental area of the rat midbrain slice. Perfusate containing GHB caused a concentration-dependent membrane hyperpolarization (EC50 = 0.88 ± 0.21 mM) and a reduction in input resistance (EC50 = 0.74 ± 0.21 mM). The highest concentration of GHB studied (10 mM) hyperpolarized neurons by 20 ± 3 mV and reduced input resistance by 58% ± 9%. Changes in membrane potential and input resistance were blocked by the γ-aminobutyric acid antagonist CGP-35348 (300 μM), but neither bicuculline (30 μM) nor strychnine (10 μM) was an effective antagonist. Voltage-clamp recordings demonstrated that GHB (1 mM) evoked 80 ± 6 pA of outward current (at −60 mV) that reversed at −110 mV (in 2.5 mM K+). Increasing concentrations of extracellular K+ progressively shifted the reversal to more depolarized potentials. In tetrodotoxin (0.3 μM) and tetraethylammonium (10 mM), depolarizing voltage steps (to −30 mV) evoked calcium-dependent current spikes that were completely blocked by GHB (1 mM). These data suggest that GHB is an agonist at γ-aminobutyric acid receptors and would be expected to inhibit DA release by causing K+-dependent membrane hyperpolarization.
Footnotes
-
Send reprint requests to: Steven W. Johnson, M.D., Ph.D., Department of Physiology & Pharmacology, L-334, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon 97201.
-
↵1 This work was supported by USPHS grants MH40416 and DA07262.
- Abbreviations:
- aCSF
- artificial cerebrospinal fluid
- BMI
- bicuculline methiodide
- DA
- dopamine
- Erev
- reversal potential
- GABA
- γ-aminobutyric acid
- GHB
- γ-hydroxybutyric acid
- SN
- substantia nigra
- TEA
- tetraethylammonium
- TTX
- tetrodotoxin
- VTA
- ventral tegmental area
- Received November 12, 1997.
- Accepted May 22, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|